Arialys Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Arialys Therapeutics, Inc. - overview
Established
2022
Location
La Jolla, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2022 by its CSO Mitsuyuki Matsumoto, Arialys Therapeutics, Inc. operates as a biotechnology company dedicated to advancing the treatment landscape for autoimmune neuropsychiatric diseases. In September 2023, Arialys Therapeutics, Inc. raised USD 58 million in seed funding from Alexandria Venture Investments, Avalon Bio Ventures, Catalys Pacific, Johnson & Johnson Innovation, and MPM BioImpact.
As of September 2023, the company is led by its CEO Jay Lichter. Arialys Therapeutics has developed a therapeutic called ART5803, an antibody designed to address anti-NMDA receptor encephalitis (ANRE), a life-threatening neurological disease linked to NMDA receptor autoantibodies. ART5803 decreases the behavioral symptoms caused by NMDAR autoantibody pathogenicity in the brain. The company plans to use the seed funding to support the advancement of pathogenic autoantibody medicines and the expansion of treatment for neuropsychiatric diseases.
Current Investors
Alexandria Venture Investments, Johnson & Johnson Innovation, MPM BioImpact
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.arialysrx.com
Verticals
Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Arialys Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.